Convergence Investment Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Convergence Investment Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.97M	Buy	344,765 +180,451	+110%	+$2.47M	0.57%	55
2026 Q1	$2.04M	Buy	164,314 +17,884	+12%	+$240K	0.33%	104
2025 Q4	$1.85M	Buy	146,430 +49,513	+51%	+$567K	0.37%	90
2025 Q3	$970K	Sell	96,917 -62,852	-39%	-$564K	0.22%	163
2025 Q2	$1.29M	Buy	159,769 +4,650	+3%	+$35.1K	0.33%	106
2025 Q1	$1.3M	Sell	155,119 -52,890	-25%	-$441K	0.36%	92
2024 Q4	$1.65M	Buy	208,009 +41,161	+25%	+$345K	0.37%	97
2024 Q3	$1.39M	Buy	166,848 +23,633	+17%	+$185K	0.37%	89
2024 Q2	$909K	Buy	+143,215	New	+$909K	0.27%	121

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Convergence Investment Partners's AMRX Position: Q2 2026 in Review

Convergence Investment Partners increased its Amneal Pharmaceuticals (AMRX) stake by 110% in Q2 2026, buying an estimated $2.47M and bringing the position to 344,765 shares worth $5.97M. The position accounts for 0.57% of the portfolio, ranked #55.

Convergence Investment Partners first reported a position in AMRX in Q2 2024 and has held it in 9 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Convergence Investment Partners held 344,765 shares of Amneal Pharmaceuticals worth $5.97M as of Q2 2026.
Convergence Investment Partners bought 180,451 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.47M.
Amneal Pharmaceuticals made up 0.57% of Convergence Investment Partners's portfolio in Q2 2026, its #55 holding.
Convergence Investment Partners first reported a position in Amneal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.